Kolexia
Robinet Gilles Pneumologie
Robinet Gilles
Pneumologie
Hôpital Morvan
Brest, France
160 Activités
180 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Métastase tumorale Carcinomes Tumeurs du cerveau Carcinome épidermoïde Adénocarcinome Adénocarcinome pulmonaire

Collaborateurs

Voir plus
Chouaid Christos
Chouaid Christos
Centre Hospitalier Intercommunal Créteil, Créteil, France
Monnet Isabelle
Monnet Isabelle
Centre Hospitalier Intercommunal Créteil, Créteil, France
Descourt Renaud
Descourt Renaud
Hôpital Morvan, Brest, France
Vergnenegre Alain
Vergnenegre Alain
Hôpital Dupuytren, Limoges, France

Industries

Voir plus
A+A
38 collaboration(s)
Dernière en 2023
IQVIA
17 collaboration(s)
Dernière en 2022
B3TSI
15 collaboration(s)
Dernière en 2023
Sanofi
13 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced -Mutant Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   07 février 2024
BREC: Multicenter Phase III, Randomized Study to Evaluate Treatment Customized According to RAP80 and BRCA1 Assessment in Patients With Advanced Non-small-cell Lung Cancer
Essai Clinique (Spanish Lung Cancer Group)   29 janvier 2024
MYSTIC: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).
Essai Clinique (AstraZeneca)   16 janvier 2024
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.
Annals of oncology : official journal of the European Society for Medical Oncology   11 septembre 2023
10 Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial
Abstract Book of the European Lung Cancer Congress (ELCC) 2023   01 avril 2023
13MO Safety and efficacy of tusamitamab ravtansine in combination with pembrolizumab ± chemotherapy in patients with CEACAM5-positive nonsquamous NSCLC (CARMEN-LC05 phase II study)
Abstract Book of the European Lung Cancer Congress (ELCC) 2023   01 avril 2023
MAPS: A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM)
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   10 mars 2023
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
Annals of oncology : official journal of the European Society for Medical Oncology   28 février 2023
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
Lung cancer (Amsterdam, Netherlands)   27 février 2023
Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29).
Translational lung cancer research   23 février 2023